Kesimpta (ofatumumab) vs Briumvi (ublituximab-xiiy)
Kesimpta (ofatumumab) vs Briumvi (ublituximab-xiiy)
Kesimpta (ofatumumab) and Briumvi (ublituximab-xiiy) are both monoclonal antibodies used in the treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. Kesimpta is a fully human anti-CD20 monoclonal antibody administered through subcutaneous injections once monthly after an initial loading dose, and it works by depleting B cells that are thought to play a role in the damaging inflammatory process of MS. Briumvi is a glycoengineered anti-CD20 monoclonal antibody administered via intravenous infusion with a unique dosing schedule that includes an induction phase followed by maintenance infusions every six months, and it similarly targets B cells to modify the disease course of MS. When deciding which medication is right for an individual, considerations may include the route of administration preference, dosing schedule, potential side effects, and how the medication's action may fit with their specific disease characteristics and lifestyle. It is essential for patients to consult with their healthcare provider to evaluate their medical history, current health condition, and treatment goals to make an informed decision on the appropriate therapy.
Difference between Kesimpta and Briumvi
Metric | Kesimpta (ofatumumab) | Briumvi (ublituximab-xiiy) |
---|---|---|
Generic name | Ofatumumab | Ublituximab-xiiy |
Indications | Relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults | Relapsing forms of multiple sclerosis (MS) |
Mechanism of action | CD20-directed cytolytic antibody | CD20-directed cytolytic antibody |
Brand names | Kesimpta | Briumvi |
Administrative route | Subcutaneous injection | Intravenous infusion |
Side effects | Upper respiratory tract infection, headache, injection-related reactions, and local injection site reactions | Infusion reactions, headache, fatigue, fever, and rash |
Contraindications | Active hepatitis B infection, active infection | Active hepatitis B, active infection |
Drug class | Monoclonal antibody | Monoclonal antibody |
Manufacturer | Novartis | TG Therapeutics |
Efficacy
Efficacy of Kesimpta (Ofatumumab) in Multiple Sclerosis
Kesimpta (ofatumumab) is a CD20-directed cytolytic monoclonal antibody approved by the U.S. Food and Drug Administration (FDA) for the treatment of relapsing forms of multiple sclerosis (MS), which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. Clinical trials have demonstrated the efficacy of Kesimpta in reducing the annualized relapse rate (ARR) in patients with MS. In the ASCLEPIOS I and II phase III trials, ofatumumab significantly reduced the ARR by over 50% compared to teriflunomide, a commonly used MS therapy. Additionally, Kesimpta showed a reduction in the number of gadolinium-enhancing T1 lesions and new or enlarging T2 lesions on MRI, which are key markers of MS disease activity.
Efficacy of Briumvi (Ublituximab-xiiy) in Multiple Sclerosis
Briumvi (ublituximab-xiiy) is another CD20-directed cytolytic monoclonal antibody, which has been studied for its potential in treating relapsing forms of multiple sclerosis. While Briumvi is not yet approved by the FDA for MS, clinical trial data has shown promising results. In phase II and III clinical trials, ublituximab-xiiy demonstrated a significant reduction in annualized relapse rates in comparison to placebo or other MS therapies. Furthermore, participants receiving Briumvi exhibited fewer MRI-detected lesions, which suggests a decrease in inflammatory activity associated with MS.
Comparative Efficacy in Multiple Sclerosis Treatment
Both Kesimpta and Briumvi target the CD20 molecule on B cells, which are believed to play a key role in the pathophysiology of MS. By depleting these B cells, both medications aim to modulate the immune response that contributes to myelin and neuronal damage in MS. While direct comparative studies between Kesimpta and Briumvi are not available, each has been shown to be effective in its own clinical trials. The choice of therapy may depend on various factors, including patient-specific considerations, tolerability, administration preferences, and other clinical factors.
Conclusion
In conclusion, Kesimpta and Briumvi represent advances in the treatment of multiple sclerosis by targeting B cells. Kesimpta has been approved for use in adults with relapsing forms of MS and has demonstrated a significant reduction in relapse rates and MRI lesions. Briumvi, while not yet approved, has shown efficacy in clinical trials in reducing relapse rates and lesion counts. As therapeutic options for MS expand, the efficacy of these treatments offers hope for better disease management and improved quality of life for patients living with this chronic condition.
Regulatory Agency Approvals
Kesimpta
Briumvi
Access Kesimpta or Briumvi today
If Kesimpta or Briumvi are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us